Surani Fernando

Most recent articles by Surani Fernando

Pipeline Report 2023: Game on for blockbusters, novel MOAs and practice-changing drugs
Pipeline Report 2023: Game on for blockbusters, novel MOAs and practice-changing drugs
Surani Fernando
October 10, 2023
11:00 am

The industry awaits a number of readouts and approvals for drugs that address market gaps and enrich treatment landscapes — with huge sales potential to boot.

Real-world data in a post-pandemic world
Real-world data in a post-pandemic world
Surani Fernando
September 15, 2023
11:00 am

COVID-19 proved a galvanizing event for the use of real-world data. Has its momentum endured?

A changing climate: The healthcare industry looks at environmental practices
A changing climate: The healthcare industry looks at environmental practices
Surani Fernando
January 30, 2023
10:30 am

Health systems and pharmaceutical companies will increasingly be relied upon to push back against the effects of surging temperatures and extreme weather events. Are they up to the task?

Pipeline Report 2022: Patient experience takes center stage
Pipeline Report 2022: Patient experience takes center stage
Surani Fernando
December 7, 2022
11:30 am

The past two years were all about COVID-19 vaccines and therapeutics. Now, imminent approvals in oncology, hematology and autoimmune disorders are set to enhance patient convenience.

Pipeline Report: Several blockbuster drugs are poised to go bigger and broader
Pipeline Report: Several blockbuster drugs are poised to go bigger and broader
Surani Fernando
November 2, 2021
12:00 pm

Therapies in the oncology, neurology and autoimmune disease pipelines could soon pose challenges to existing standards of care.

Pipeline Report 2021: Promising drugs tick along across a range of conditions
Pipeline Report 2021: Promising drugs tick along across a range of conditions
Surani Fernando
December 8, 2020
5:00 am

COVID vaccines and therapeutics receive all the headlines — with good reason — but the pharma pipeline is bursting with A-grade candidates across a range of conditions.

Biogen’s touted Alzheimer’s drug receives thumbs-down from FDA advisory panel
Biogen’s touted Alzheimer’s drug receives thumbs-down from FDA advisory panel
Surani Fernando
November 9, 2020
5:00 am

The agency will issue its final verdict on approval in March.

  • From Our Partners